Clinical Trial

A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

Study acronym: TRIlogy-4
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate how well JNJ-79635322 works when compared with an anti-B-cell maturation antigen (BCMA)xCD3 bispecific antibody.
Protocol Amendment History 6 changes
critical Primary endpoint(s) modified 2026-07-17
notable Trial sites expanded: 103 -> 109 locations 2026-07-17
notable Trial sites expanded: 65 -> 103 locations 2026-07-07
notable Trial sites expanded: 43 -> 65 locations 2026-06-06
notable Trial sites expanded: 39 -> 43 locations 2026-05-09
notable Trial sites expanded: 33 -> 39 locations 2026-04-14
Trial Details
NCT Number NCT07258511
Lead Sponsor Janssen Research & Development, LLC
Conditions Multiple Myeloma
Enrollment 400 participants
Start Date 2026-02-04
Primary Completion 2028-12-12 (estimated)
Study Completion 2031-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-16